# A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

> **NCT05060406** · PHASE3 · UNKNOWN · sponsor: **Luye Pharma Group Ltd.** · enrollment: 448 (estimated)

## Conditions studied

- Postmenopausal Osteoporosis

## Interventions

- **DRUG:** LY06006

## Key facts

- **NCT ID:** NCT05060406
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-30
- **Primary completion:** 2021-09-30
- **Final completion:** 2021-12-31
- **Target enrollment:** 448 (ESTIMATED)
- **Last updated:** 2021-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05060406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05060406, "A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05060406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*